BioFrontier Partners, Inc.
Venture capitalTokyo · Series A–Late Stage · 11 people tracked
Investment thesis
BioFrontier Partners, Inc. is a Japan-based biotech-focused investment firm headquartered in Tokyo, with an additional presence in San Diego, USA.
Source: firm website, verified Jul 29, 2026.
Team · 11 people
from the firm's website & public directoriesFrequently asked questions
- What stage does BioFrontier Partners, Inc. invest at?
- BioFrontier Partners, Inc. invests at the Series A, Series B, Series C, Late Stage stages.
- What is BioFrontier Partners, Inc.'s typical check size?
- BioFrontier Partners, Inc. typically writes checks of $500K – $3M.
- What sectors does BioFrontier Partners, Inc. focus on?
- BioFrontier Partners, Inc. focuses on Biotech, Medical Devices.
- Where is BioFrontier Partners, Inc. located?
- BioFrontier Partners, Inc. is headquartered in Tokyo, JP.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Excel Venture Management is a venture capital firm that builds and invests in companies applying life science technologies to problems in healthcare and other areas.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.







